Clarkston Capital Partners LLC Grows Holdings in Becton, Dickinson and Company $BDX

Clarkston Capital Partners LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 27.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 376,835 shares of the medical instruments supplier’s stock after purchasing an additional 80,092 shares during the quarter. Becton, Dickinson and Company accounts for about 1.5% of Clarkston Capital Partners LLC’s holdings, making the stock its 23rd largest holding. Clarkston Capital Partners LLC owned 0.13% of Becton, Dickinson and Company worth $70,532,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 15.4% during the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after buying an additional 4,305,947 shares during the period. Norges Bank purchased a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $653,377,000. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 24.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after acquiring an additional 1,670,590 shares during the last quarter. Laurel Wealth Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 16,974.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock worth $272,049,000 after acquiring an additional 1,570,136 shares during the last quarter. Finally, First Eagle Investment Management LLC boosted its position in shares of Becton, Dickinson and Company by 13.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after purchasing an additional 1,208,218 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BDX shares. JPMorgan Chase & Co. lowered their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Bank of America increased their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, TD Cowen increased their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Stock Down 1.5%

BDX stock opened at $167.31 on Monday. The stock has a market capitalization of $47.64 billion, a PE ratio of 27.29, a price-to-earnings-growth ratio of 12.12 and a beta of 0.24. The company has a fifty day moving average of $193.26 and a 200-day moving average of $191.16. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,416 shares of company stock valued at $674,693 over the last 90 days. 0.40% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.